Search hospitals > Utah > Salt Lake City

University of Utah

Claim this profile
Salt Lake City, Utah 84108
Global Leader in Fibrosis
Global Leader in Heart Failure
Conducts research for Stroke
Conducts research for Syndrome
Conducts research for Muscular Dystrophy
1118 reported clinical trials
135 medical researchers
Photo of University of Utah in Salt Lake CityPhoto of University of Utah in Salt Lake CityPhoto of University of Utah in Salt Lake City

Summary

University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Fibrosis, Heart Failure, Stroke, Syndrome, Muscular Dystrophy and other specialties. University of Utah is involved with conducting 1,118 clinical trials across 1,389 conditions. There are 135 research doctors associated with this hospital, such as Benjamin Maughan, MD, Wallace L. Akerley, Torri Metz, MD, and Juan Gallegos-Orozco, MD.

Area of expertise

1Fibrosis
Global Leader
University of Utah has run 74 trials for Fibrosis. Some of their research focus areas include:
rs3570920 TT positive
621+1G->T
CFTR
2Heart Failure
Global Leader
University of Utah has run 67 trials for Heart Failure. Some of their research focus areas include:
BAROSTIM

Top PIs

Clinical Trials running at University of Utah

Thrombotic Thrombocytopenic Purpura
Multiple Sclerosis
Stroke
Interstitial Lung Disease
Chronic Kidney Disease
Opioid Use Disorder
Emergency
Bleeding
Kidney Disease
Patent Ductus Arteriosus
Image of trial facility.

Caplacizumab + Immunosuppression

for Thrombotic Thrombocytopenic Purpura

This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary endpoint of remission in male and female participants aged 18 to 80 years with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The anticipated study duration per participant without a recurrence while on therapy is maximum 24 weeks (ie, approximately 1 day for screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up). Participants will have daily assessments during hospitalization and weekly visits for assessments during ongoing treatment with caplacizumab and IST. There will be 3 outpatient visits for assessments during the follow-up period. There will be two additional follow-up visits for participants who do not have ADAMTS13 activity levels of ≥50% at the time of caplacizumab discontinuation.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

TAK-755

for Thrombotic Thrombocytopenic Purpura

This is a study of TAK-755 in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main aim of this study is to determine the percentage of participants with a clinical response without plasma exchange during the study. Participants who have an acute attack of iTTP will receive TAK-755 and immunosuppressive therapy during their stay at the hospital until they achieve a clinical response. Participants will also be treated with TAK-755 for an additional time of up to 6 weeks after the acute phase. In total, participants will stay in the study for approximately 3 months.
Recruiting1 award Phase 25 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Utah?
University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Fibrosis, Heart Failure, Stroke, Syndrome, Muscular Dystrophy and other specialties. University of Utah is involved with conducting 1,118 clinical trials across 1,389 conditions. There are 135 research doctors associated with this hospital, such as Benjamin Maughan, MD, Wallace L. Akerley, Torri Metz, MD, and Juan Gallegos-Orozco, MD.
Where is University of Utah located?
**Directions to University of Utah Hospital, Salt Lake City:** - **By Car:** Take I-15 N and exit at 310B for 400 S. Proceed by turning left onto 500 E, then make a right onto N Campus Dr. - **Public Transit:** The nearest station is U Medical Center Station, which is a 7-minute walk to the hospital.
Who should I call to ask about financial aid or insurance network?
**University of Utah Hospital Financial Assistance and Insurance Information:** - For financial assistance, contact: 801-587-6303 or 800-862-4937. Assistance is based on household income relative to federal guidelines. - Insurance inquiries: Contact the Patient Accounting Department at 801-587-6303 or 800-862-4937. - Accepted insurances at Huntsman Cancer Institute include Aetna, Blue Cross Blue Shield, Cigna, DMBA, PEHP, Select Health, Tricare, United Healthcare (Options PPO), University of Utah Health Plans, Medicare, and Medicaid.
What insurance does University of Utah accept?
The University of Utah Health system accepts a wide range of insurance plans, including most major commercial health plans, traditional Medicare, Utah Medicaid, and many Medicaid HMOs. It is in-network with out-of-state Blue Cross Blue Shield plans that have a suitcase logo on the insurance ID card, indicating BlueCard eligibility. However, ACA/Insurance Marketplace plans, including those from Cigna, are NOT in-network with University of Utah Health facilities and physicians.
What awards or recognition has University of Utah received?
The University of Utah Hospital, located in Salt Lake City, Utah, is renowned for its groundbreaking research and exceptional patient care. It was honored with a $5.4 million Javits Award to support research into migraine origins. Furthermore, neurobiologist Moriel Zelikowsky, Ph.D., was awarded the McKnight Scholar Award for her studies on the effects of social isolation, highlighting the hospital's dedication to medical advancement.